OS Therapies Inc. said it entered into a March 4, 2026 securities purchase agreement with accredited investors for a $2.0 million private placement. The company issued $2.2 million aggregate principal amount of 10% original issue discount unsecured convertible promissory notes and warrants to buy up to 1,666,667 shares of common stock. Proceeds are expected to support clinical development, R&D programs, and general corporate purposes, with a 7% cash placement agent fee plus $25,000 in expenses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-024726), on March 06, 2026, and is solely responsible for the information contained therein.